Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

5 May 2020

Abstract excerpt

Multiple myeloma is a plasma cell malignancy that escapes from apoptosis by heterogeneously over-expressing anti-apoptotic BCL2 proteins. Myeloma cells with a t(11;14) translocation present a particular vulnerability to BCL2 inhibition while a majority of myeloma cells relies on MCL1 for survival. The present study aimed to determine whether the combination of BCL2 and MCL1 inhibitors at low doses could be of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32371863
DOI: 10.1038/s41419-020-2505-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexesPMID 32371863Read ↗

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read ↗

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature reviewSemantic proximity Read ↗

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsSemantic proximity Read ↗

ABT-737 is highly effective against molecular subgroups of multiple myelomaSemantic proximity Read ↗

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myelomaSemantic proximity Read ↗

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read ↗

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaSemantic proximity Read ↗

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.Semantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy BiomarkerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.